FibroBiologics Inc. (NASDAQ: FBLG) announced the pricing of a public offering of 2,272,728 shares of common stock and accompanying warrants at $1.32 per share. The biotechnology company expects to raise approximately $3 million in gross proceeds before fees and expenses.

The warrants will have an exercise price of $1.32 per share and will expire five years after stockholder approval of the warrant issuance. If fully exercised, the warrants could generate an additional $3 million for the company, though no assurance exists that warrant holders will exercise their rights.

H.C. Wainwright & Co. serves as the exclusive placement agent for the offering, which is expected to close on or about April 2, 2026, subject to customary closing conditions. The company plans to use net proceeds for working capital and general corporate purposes.

The securities are being offered under a registration statement on Form S-1 that was declared effective by the Securities and Exchange Commission on March 31, 2026. The offering requires stockholder approval before warrant exercise can begin.

Houston-based FibroBiologics develops treatments for chronic diseases using fibroblast cells and fibroblast-derived materials. The clinical-stage company holds over 270 issued and pending patents across various therapeutic areas including wound healing, multiple sclerosis, and cancer treatment.